Immunophenotypically, BPDCN is characterized by co-expression of CD4, CD56, and CD123 while lacking lineage-specific markers for T-, B-, or myeloid cells [3, 4]. This evidence concerns the gene NCAM1 and CD4+/CD56+ hematodermic neoplasm.